Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
03 oct. 2023 05h00 HE
|
Alvotech
REYKJAVIK, Iceland and PISCATAWAY, N.J., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines...
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
02 oct. 2023 07h30 HE
|
SAB Biotherapeutics, Inc.
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
Senti Bio to Participate in Upcoming Conferences
26 sept. 2023 16h05 HE
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing a new generation of cell and gene therapies...
Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®
25 sept. 2023 04h00 HE
|
Alvotech
REYKJAVIK, Iceland, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Inventiva et Hepalys Pharma, Inc., signent un accord de licence exclusif pour développer et commercialiser lanifibranor au Japon et en Corée du Sud
20 sept. 2023 16h00 HE
|
INVENTIVA
Hepalys Pharma, Inc. est une nouvelle société créée par Catalys Pacific, et dans laquelle Inventiva détient une participation de 30%. Dans le cadre de l’accord de licence exclusif, Inventiva...
Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea
20 sept. 2023 16h00 HE
|
INVENTIVA
Hepalys Pharma, Inc. is a new company created by Catalys Pacific and in which Inventiva has a 30% ownership position. Under the exclusive licensing agreement, Inventiva will receive a $10 million...
Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)
20 sept. 2023 04h30 HE
|
Alvotech
REYKJAVIK, Iceland, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for...
AiViva Biopharma Appoints Lester J. Kaplan, PhD to the Board of Directors
18 sept. 2023 06h00 HE
|
AiViva Biopharma
COSTA MESA, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company developing innovative therapies to address major unmet medical needs, today...
BetterLife Pharma to Host Investors Update Call on September 18, 2023
14 sept. 2023 08h00 HE
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...
BetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001
12 sept. 2023 08h00 HE
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, Sept. 12, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...